Differential expression of syndecans and glypicans in chronically inflamed synovium

Annals of the Rheumatic Diseases

Volumn 67, Issue 5, 2008, Pages 592-601

  Patterson, A M ^a   Cartwright, A ^a   David, G ^b   Fitzgerald, O ^c   Bresnihan, B ^c   Ashton, B A ^a   Middleton, J ^a  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; AZATHIOPRINE; GLYPICAN; GLYPICAN 1; GLYPICAN 3; GLYPICAN 4; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PROTEOHEPARAN SULFATE; SALAZOSULFAPYRIDINE; STEROID; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; SYNDECAN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; OSTEOARTHRITIS; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SMOOTH MUSCLE FIBER; SYNOVITIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLYPICANS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS; SYNDECAN-1; SYNDECAN-2; SYNDECAN-3; SYNDECANS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 42449148694     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.063875     Document Type: Article

References (61)

1. Bernfield M, Gotte M, Park PE, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-77.
2. Esko JD, Lindahl, U. Molecular diversity of heparan sulphate. J Clin Invest 2001;108:169-73.
3. Kojima T. Molecular biology of ryudocan, an endothelial heparan sulfate proteoglycan. Semin Thromb Hemost 2000;26:67-73.
4. Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J 1997;327:1-16.
5. Rapraeger AC. Molecular interactions of syndecans during development. Semin Cell Dev Biol 2001;12:107-16.
6. Beauvais DM, Rapraeger AC. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2004;2:3.
7. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 1992;267:20435-43.
8. Lundqvist K, Schmidtchen A. Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers. Br J Dermatol 2001;144:254-9.
9. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002;277:29730-6.
10. van Horssen J, Kleinnijenhuis J, Maass C N, Rensink A A, Otte-Holler I, David G. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol Aging 2002;23:537-45.
11. Kosher RA. Syndecan-3 in limb skeletal development. Microsc Res Tech 1998;43:123-30.
12. Pfander D, Swoboda B, Kirsch T. Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes. Am J Pathol 2001;159:1777-83.
13. Casar JC, Cabello-Verrugio C, Olguin H, Aldunate R, Inestrosa NC, Brandan E. Heparan sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of syndecan-3 for successful fiber formation. J Cell Sci 2004;117:73-84.
14. Patterson AM, Gardner L, Shaw J, David G, Loreau E, Aguilar L, et al. Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. Arthritis Rheum 2005;52:2331-42.
15. Fransson LA, Belting M, Cheng F, Jonsson M, Mani K, Sandgren S. Novel aspects of glypican glycobiology. Cell Mol Life Sci 2004;61:1016-24.
16. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
17. Firestein GS. Rheumatoid synovitis and pannus. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby, 1998:13.1-13.24.
18. Gotte M. Syndecans in inflammation. FASEB J 2003;17:575-91.
19. Gotte M, Joussen AM, Klein C, Andre P, Wagner DD, Hinkes MT, et al. Role of syndecan-1 in leukocyte-endothelial interactions in the ocular vasculature. Invest Ophthalmol Vis Sci 2002;43:1135-41.
20. Slimani H, Charnaux N, Mbemba E, Saffar L, Vassy R, Vita C, et al. Interaction of RANTES with syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochim Biophys Acta 2003;1617:80-8.
21. Hamon M, Mbemba E, Charnaux N, Slimani H, Brule S, Saffar L, et al. A syndecan-4/CXCR4 complex expressed on human primary lymphocytes and macrophages and HeLa cell line binds the CXC chemokine stromal cell-derived factor-1 (SDF-1). Glycobiology 2004;14:311-23.
22. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002;111:635-46.
23. Marshall LJ, Ramdin LS, Brooks T, DPhil PC, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003;171:2057-65.
24. Halden Y, Rek A, Atzenhofer W, Szilak L, Wabnig A, Kungl AJ. Interleukin-8 binds to syndecan-2 on human endothelial cells. Biochem J 2004;377:533-8.
25. Kop EN, Kwakkenbos MJ, Teske GJ, Kraan MC, Smeets TJ, Stacey M, et al. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis Rheum 2005;52:442-50.
26. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT. Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 1992;267:10337-41.
27. Spillman D, Witt D, Lindahl U. Defining the interleukin-8 binding domain of heparan sulfate. J Biol Chem 1998;273:15487-93.
28. Middleton J, Patterson A, Gardner L, Schmutz C, Ashton B. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002;100:3853-60.
29. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol 2003;4:926-37.
30. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans - as exemplified by chemokines. Annu Rev Biochem 2005;74:385-410.
31. Lories V, Cassiman JJ, Van den Berghe H, David G. Multiple distinct membrane heparan sulfate proteoglycans in human lung fibroblasts. J Biol Chem 1989;264:7009-16.
32. David G, Lories V, Decock B, Marynen P, Cassiman JJ, Van den Berghe H. Molecular cloning of a phosphatidylinositol-anchored membrane heparan sulfate proteoglycan from human lung fibroblasts. J Cell Biol 1990;111:3165-76
33. David G, van der Schueren B, Marynen P, Cassiman JJ, van den Berghe H. Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells. J Cell Biol 1992;118:961-9
34. Lories V, Cassiman JJ, Van den Berghe H, David G. Differential expression of cell surface heparan sulfate proteoglycans in human mammary epithelial cells and lung fibroblasts. J Biol Chem 1992;267:1116- 22
35. Roskams T, Moshage H, De Vos R, Guido D, Yap P, Desmet V. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995;21:950-8
36. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, et al. A plasmocyte selective monoclonal antibody (B-B4) recognises syndecan-1. Br J Haematol 1996;94:318-23.
37. Siebertz B, Stocker G, Drzeniek Z, Handt S, Just U, Haubeck HD. Expression of glypican-4 in haematopoietic-progenitor and bone-marrow-stromal cells. Biochem J 1999;344:937-43.
38. Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 1998;185:290-7.
39. Dodge GR, Boesler EW, Jimenez SA. Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells. Lab Invest 1995;73:649-57.
40. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, et al. Biology of the syndecans: a family of transmembrane heparan sulphate proteoglycans. Annu Rev Cell Biol 1992;8:365-93.
41. Kopper L, Sebestyen A. Syndecans and the lymphoid system. Leukaemia Lymphoma 2000;38:271-81.
42. Sanderson RD, Borset M. Syndecan-1 in B lymphoid malignancies. Ann Hematol 2002;81:125-35.
43. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:R569-80.
44. Salvador G, Sanmarti R, Garcia-Peiro A, Rodriguez-Cros JR, Munoz-Gomez J, Canete JD. p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage. Ann Rheum Dis 2005;64:183-7.
45. Oh ES, Couchman JR. Syndecans-2 and -4; close cousins, but not identical twins. Mol Cells 2004;17:181-7.
46. Essner JJ, Chen E, Ekker SC. Syndecan-2. Int J Biochem Cell Biol 2006;38:152-6.
47. Floris S, van den Born J, van der Pol SM, Dijkstra CD, De Vries HE. Heparan sulfate proteoglycans modulate monocyte migration across cerebral endothelium. J Neuropathol Exp Neurol 2003;62:780-90.
48. Chen E, Hermanson S, Ekker SC. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood 2004;103:1710-19.
49. Roskams T, Rosenbaum J, De Vos R, David G, Desmet V. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases. Hepatology 1996;24:524-32.
50. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 2004;10:5178-86.
51. Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 2005;6:902-10.
52. Weiner OH, Zoremba M, Gressner AM. Gene expression of syndecans and betaglycan in isolated rat liver cells. Cell Tissue Res 1996;285:11-16.
53. Kirsch T, Koyama E, Liu M, Golub E E, Pacifici M. Syndecan-3 is a selective regulator of chondrocyte proliferation. J Biol Chem 2002;277:42171-7.
54. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005;33:1402-16.
55. Ybot-Gonzalez P, Copp AJ, Greene ND. Expression pattern of glypican-4 suggests multiple roles during mouse development. Dev Dyn 2005;233:1013-7.
56. Hagihara K, Watanabe K, Chun J, Yamaguchi Y. Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 2000;219:353-67.
57. Singh JA, Arayssi T, Duray P, Schumacher HR. Immunohistochemistry of normal human knee synovium: a quantitative study. Ann Rheum Dis 2004;63:785-90.
58. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997;91: 385-95.
59. Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ Res 2005;96:488-500.
60. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002;4:S81-90.
61. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002;71:435-71.